• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany.

作者信息

Buttmann Mathias, Weber Martin S, Meuth Sven G, Blümich Sandra, Hieke-Schulz Stefanie, Dirks Petra, Eggebrecht Julius C, Ziemssen Tjalf

机构信息

Department of Neurology, Caritas Hospital, Bad Mergentheim, Germany.

Department of Neurology, Institute of Neuropathology, University Medicine Göttingen, Göttingen, Germany.

出版信息

Front Neurol. 2025 May 21;16:1564327. doi: 10.3389/fneur.2025.1564327. eCollection 2025.

DOI:10.3389/fneur.2025.1564327
PMID:40470489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12135804/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/df669e1151bb/fneur-16-1564327-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/7b802c917f62/fneur-16-1564327-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/a016fbf298d1/fneur-16-1564327-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/9ca31bcfd609/fneur-16-1564327-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/13a4ae9d01bd/fneur-16-1564327-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/20a8840de206/fneur-16-1564327-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/85ffb48d3dba/fneur-16-1564327-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/df669e1151bb/fneur-16-1564327-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/7b802c917f62/fneur-16-1564327-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/a016fbf298d1/fneur-16-1564327-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/9ca31bcfd609/fneur-16-1564327-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/13a4ae9d01bd/fneur-16-1564327-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/20a8840de206/fneur-16-1564327-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/85ffb48d3dba/fneur-16-1564327-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7e8/12135804/df669e1151bb/fneur-16-1564327-g007.jpg

相似文献

1
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany.信心治疗成功：奥瑞珠单抗在德国的长期真实世界有效性和安全性
Front Neurol. 2025 May 21;16:1564327. doi: 10.3389/fneur.2025.1564327. eCollection 2025.
2
Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.一项评估奥瑞珠单抗在德国真实世界多发性硬化症队列中长期安全性和有效性的非干预性上市后研究的设计 - CONFIDENCE 研究方案。
BMC Neurol. 2020 Mar 14;20(1):95. doi: 10.1186/s12883-020-01667-7.
3
Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study.在德国初治奥瑞珠单抗的多发性硬化症患者真实世界队列中的安全性、依从性和持续性：CONFIDENCE研究的初步见解
Front Neurol. 2022 May 9;13:863105. doi: 10.3389/fneur.2022.863105. eCollection 2022.
4
Ocrelizumab: A Review in Multiple Sclerosis.奥瑞珠单抗：多发性硬化症的治疗药物。
Drugs. 2022 Feb;82(3):323-334. doi: 10.1007/s40265-022-01672-9. Epub 2022 Feb 22.
5
Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients.奥瑞珠单抗在多发性硬化症中的真实世界应用：128例患者的单中心经验。
J Neurol Sci. 2020 Aug 15;415:116973. doi: 10.1016/j.jns.2020.116973. Epub 2020 Jun 11.
6
Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.奥瑞珠单抗治疗多发性硬化症：一项丹麦基于人群的队列研究。
Eur J Neurol. 2022 Feb;29(2):496-504. doi: 10.1111/ene.15142. Epub 2021 Oct 26.
7
Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.奥瑞珠单抗治疗原发性进展型多发性硬化症患者：德国同情用药项目的短期安全性结果。
Clin Neurol Neurosurg. 2020 Oct;197:106142. doi: 10.1016/j.clineuro.2020.106142. Epub 2020 Aug 12.
8
Ocrelizumab for the treatment of multiple sclerosis.奥瑞珠单抗治疗多发性硬化症。
Expert Rev Neurother. 2019 Feb;19(2):97-108. doi: 10.1080/14737175.2019.1561284. Epub 2018 Dec 28.
9
Real world study of ocrelizumab in multiple sclerosis: Kuwait experience.奥瑞珠单抗在多发性硬化症中的真实世界研究：科威特经验。
Mult Scler Relat Disord. 2023 Nov;79:104941. doi: 10.1016/j.msard.2023.104941. Epub 2023 Aug 18.
10
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology.奥瑞珠单抗治疗多发性硬化症：安全性、有效性及药理学
Ther Clin Risk Manag. 2021 Jul 30;17:765-776. doi: 10.2147/TCRM.S282390. eCollection 2021.

本文引用的文献

1
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.用奥瑞珠单抗治疗的多发性硬化症患者感染及相关危险因素的长期分析：13项介入性临床试验的汇总分析
Ther Adv Neurol Disord. 2024 Oct 8;17:17562864241277736. doi: 10.1177/17562864241277736. eCollection 2024.
2
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.氯法拉滨与那他珠单抗、奥瑞珠单抗和阿仑单抗治疗复发缓解型多发性硬化症的疗效比较。
Mult Scler. 2024 Aug;30(9):1163-1175. doi: 10.1177/13524585241267211. Epub 2024 Aug 1.
3
Ocrelizumab in people with primary progressive multiple sclerosis: A real-world multicentric study.
奥瑞珠单抗治疗原发性进行性多发性硬化症的真实世界多中心研究。
Mult Scler Relat Disord. 2024 Sep;89:105776. doi: 10.1016/j.msard.2024.105776. Epub 2024 Jul 20.
4
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.那他珠单抗与奥瑞珠单抗治疗多发性硬化疾病进展的比较。
Ann Clin Transl Neurol. 2024 Aug;11(8):2008-2015. doi: 10.1002/acn3.52118. Epub 2024 Jul 5.
5
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.奥瑞珠单抗或那他珠单抗治疗早期高活动度复发缓解型多发性硬化症患者的 NEDA-3 达标。
Mult Scler Relat Disord. 2024 Jul;87:105594. doi: 10.1016/j.msard.2024.105594. Epub 2024 Apr 6.
6
Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers.奥瑞珠单抗治疗复发型多发性硬化症的疗效和安全性：瑞士两家多发性硬化症中心的真实世界经验。
Mult Scler Relat Disord. 2024 Jun;86:105570. doi: 10.1016/j.msard.2024.105570. Epub 2024 Mar 30.
7
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.在60岁以上的多发性硬化症患者中比较奥瑞珠单抗与干扰素/醋酸格拉替雷。
J Neurol Neurosurg Psychiatry. 2024 Jul 15;95(8):767-774. doi: 10.1136/jnnp-2023-332883.
8
Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.奥地利复发缓解型多发性硬化症患者的早期强化与递增治疗。
J Neurol. 2024 Jun;271(6):3142-3152. doi: 10.1007/s00415-024-12256-w. Epub 2024 Mar 2.
9
Mechanisms and consequences of sex differences in immune responses.免疫反应中性别差异的机制和后果。
Nat Rev Nephrol. 2024 Jan;20(1):37-55. doi: 10.1038/s41581-023-00787-w. Epub 2023 Nov 22.
10
No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].无疾病活动证据（NEDA）作为多发性硬化症的临床评估工具：临床医生和患者视角[叙述性综述]
Neurol Ther. 2023 Dec;12(6):1909-1935. doi: 10.1007/s40120-023-00549-7. Epub 2023 Oct 11.